Publications by authors named "Keith Otto"

Claim this Profile
S
Structural basis for GPR40 allosteric agonism and incretin stimulation.
Joseph D Ho, Betty Chau, Logan Rodgers, Frances Lu, Kelly L Wilbur, Keith A Otto

Nat Commun· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.
Chafiq Hamdouchi, Pranab Maiti, Alan M Warshawsky, Amy C DeBaillie, Keith A Otto

J Med Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Chafiq Hamdouchi, Steven D Kahl, Anjana Patel Lewis, Guemalli R Cardona, Richard W Zink, Keith A Otto

J Med Chem· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes.
Yanfang Liu, M Dodson Michael, Shera Kash, William R Bensch, Brett P Monia, Keith A Otto

Endocrinology· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling.
Julie S Moyers, Tatiyana L Shiyanova, Farrokh Mehrbod, James D Dunbar, Timothy W Noblitt, Keith A Otto

J Cell Physiol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Anne Reifel-Miller, Keith Otto, Eric Hawkins, Robert Barr, William R Bensch

Mol Endocrinol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis.
Guoqing Cao, Yu Liang, Carol L Broderick, Brian A Oldham, Thomas P Beyer, Keith A Otto

J Biol Chem· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis